Search
forLearn
5 / 801 resultslearn HT-B
learn oligopeptide-71
learn copper tripeptide-1
learn octapeptide-2
Research
5 / 48 resultsresearch Heat treatment increases the incidence of alopecia areata in the C3H/HeJ mouse model
Heat treatment increases hair loss in certain mice.
research Genome-wide association study in Japanese females identifies fifteen novel skin-related trait associations
Researchers found 15 new genetic links to skin traits in Japanese women.
research Association of HSPA1B SNP rs6457452 with Alopecia Areata in the Korean Population
The SNP rs6457452 is linked to a higher risk of alopecia areata in Koreans.
research Low‐Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity
Light therapy reduces scalp inflammation, boosts hair regrowth with Minoxidil 2%.
research Bioinformatics analysis of genes associated with the patchy-type alopecia areata: CD2 may be a new therapeutic target
CD2 might be a new treatment target for patchy alopecia areata.
Community Join
5 / 1000+ resultscommunity What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
community Proof DHT is not the main cause of hair loss. TRPS1 Gene and Protein might be. PP405 won’t work. AMP-303 might!
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI 115 hasn't done phase one yet for AGA?
User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.
community HMI-115 start AGA phase 2 trial volunteer in China. The eligible volunteer should be age between 18 to 65, Norwood 3 vertex , 4 and 5. And agree to prevent pregnancy. The trial is leaded by the doctor in Beijing hospital.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.